Back

Long-term clinical-pathologic results of enzyme replacement therapy in pre-hypertrophic fabry disease cardiomyopathy.

2 September 2024 (09:00 - 09:50)
Organised by: Logo
Congress Presentation Part of: New insights into pharmacotherapy for acute heart failure Pathophysiology and Mechanisms ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Cristina Chimenti

Sapienza University of Rome, Rome (Italy)

7 More presentations in this session

Presentation thumbnail
Spectrum of heart failure in 16 sub-saharan countries: drugs strategies and 8-year trends (the february study 2016-2023)
Professor I. Diop (Dakar, SN)
Abstract Slides Video
Presentation thumbnail
Combination of diuretics to overcome diuretic resistance in acute heart failure: systematic review and updated network meta-analysis
Doctor I. Girard Cunha Vieira Lima (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Effect of renin-angiotensin system inhibitors in elderly patients with heart failure and reduced ejection fraction
Doctor Y. Tamaki (Tenri, JP)
Abstract Slides Video
Presentation thumbnail
REDUCE-HF: a stronger heart go a long way
Doctor K. Kam (Shatin, HK)
Abstract Slides Video
Presentation thumbnail
Comparing treatment strategies for heart failure: a real-world analysis of adding ARNI or SGLT2i to older GDMT
Doctor P. Amornritvanich (Bangkok, TH)
Abstract Slides Video

Access the full session

Session thumbnail
New insights into pharmacotherapy for acute heart failure

The Event

Event poster

ESC Congress 2024

2 September 2024 09:00 CET
You may be interested in
thumbnail
Congress Presentation
Long-term clinical-pathologic results of enzyme replacement therapy in pre-hypertrophic Fabry disease cardiomyopathy
thumbnail
Congress Presentation
Fabry cardiomyopathy: myocardial fibrosis, inflammation and reduced mannose6phosphate receptors cause low accessibility to enzyme therapy.
thumbnail
Congress Presentation
Prognostic impact of LV GLS response in Fabry patients on enzyme replacement therapy

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources